New Ebola Vaccine Candidate Moves Towards Human Trials With $16.5m CEPI Backing

A new vaccine candidate targeting Bundibugyo ebolavirus is set to advance towards human clinical trials in Africa after receiving up to $16.5 million in funding.

The Coalition for Epidemic Preparedness Innovations (CEPI) is backing African biopharmaceutical company Minapharm Group to progress the vaccine through preclinical development and into an early-stage Phase 1 trial assessing its safety and ability to generate an immune response.

The programme comes amid efforts to develop vaccines capable of tackling the Bundibugyo ebolavirus outbreak affecting the Democratic Republic of the Congo (DRC).

Minapharm’s investigational vaccine is the fifth Bundibugyo-specific candidate being supported by CEPI as part of its response to the epidemic.

Vaccine Designed to Generate B- and T-Cell Responses

The vaccine was designed by Berlin-based ProBioGen, part of Minapharm Group, using the company’s proprietary MVA-CR19 modified vaccinia Ankara vaccine platform.

According to the developers, similar technology has been used in a licensed smallpox and mpox vaccine and has generated long-term immunity in a vaccine targeting the related Zaire ebolavirus.

CEPI says the Minapharm candidate is the only Bundibugyo vaccine it is currently funding that has been designed to induce both B- and T-cell responses, with the aim of generating comprehensive and long-lasting immunity.

“CEPI’s funding to Minapharm harnesses the growing strength of African-led innovation to help confront this increasingly severe outbreak and prepare for future threats”, said Dr Richard Hatchett, CEO of CEPI. “In just three months, cases of Bundibugyo have spread rapidly across the DRC, making this the largest and deadliest outbreak the country has ever faced. We are proud to support Minapharm’s Bundibugyo vaccine candidate: it will round out CEPI’s portfolio, give the world another shot on goal, and advance Minapharm’s proprietary MVA platform, which if successful can serve as the basis for future African-manufactured filovirus vaccines. The faster we can advance a pipeline of promising candidates, the better our chances of saving lives and bringing this epidemic under control.”

CEPI’s wider objective is to bring at least two Bundibugyo vaccines through to Emergency Use Authorisation and WHO Prequalification, both to respond to the current outbreak and improve preparedness for future epidemics.

Phase 1 Trial Expected to Take Place in Africa

Dr. Wafik Bardissi, Group Chairman and CEO of Minapharm and Chairman of ProBioGen, said: “For more than 25 years, Minapharm has built proven biologics capabilities in Egypt and, together with ProBioGen, established a cross-continental group model combining scientific innovation, proprietary technologies and advanced biomanufacturing.”

Dr. Bardissi added: “This programme demonstrates the strength of our capabilities across the full biologics continuum, from design and development through to manufacturing, in response to an urgent public-health threat. With CEPI’s support, we are turning scientific ingenuity into health sovereignty, drawing on the breadth of our technologies and know-how to advance a vaccine response for Africa.”

As part of the development process, ProBioGen will manufacture the recombinant MVA drug substance in Germany under Good Manufacturing Practice guidelines.

It will then be transported to Minapharm’s facility in Cairo, where the finished vaccine product will be produced for testing.

Minapharm also plans to transfer manufacturing of the drug substance to its biotechnology facilities in Cairo, potentially allowing both the active vaccine component and finished product to be manufactured locally.

“ProBioGen’s MVA-CR19 platform was developed to enable rapid generation of recombinant MVA vaccine candidates and scalable manufacturing,” said Dr Volker Sandig, Chief Scientific Officer of ProBioGen. “We are proud to bring this platform and our CMC expertise to a Minapharm-led programme supported by CEPI, helping advance a Bundibugyo ebolavirus vaccine candidate towards clinical evaluation in response to an urgent public-health need.”

Focus on African Vaccine Manufacturing

The programme also forms part of broader efforts to increase Africa’s capacity to develop and manufacture vaccines needed to respond to outbreaks on the continent.

Dr Jean Kaseya, Director General, Africa CDC, said, “Bundibugyo virus is now driving the largest Ebola outbreak DRC has ever faced. A vaccine candidate advanced by an African company is exactly the kind of capability our continent needs – not just for this outbreak, but so that Africa can develop and manufacture the tools it needs to protect its own people. We welcome CEPI’s support for Minapharm’s work as a concrete step toward that health sovereignty.”

If the Phase 1 trial is successful, CEPI anticipates working with Minapharm and ProBioGen on later-stage studies designed to produce efficacy data needed for potential emergency use authorisation and eventual licensing.

The organisations have also committed to working towards rapid and affordable supplies for affected countries if the vaccine is ultimately demonstrated to be safe and effective.

CEPI is already supporting Bundibugyo vaccine candidates using several different technologies, including mRNA, ChAdOx and rVSV platforms, as researchers race to develop effective tools against the outbreak.